Prokinetics are medications that strengthen and coordinate the muscular contractions in your digestive tract, helping food move through your stomach and intestines more efficiently. They’re prescribed when the normal wave-like motion of digestion slows down or becomes disorganized, leading to symptoms like nausea, bloating, and feeling uncomfortably full after eating.
How Prokinetics Work
Your digestive system moves food along through rhythmic muscle contractions, similar to how you squeeze a tube of toothpaste from the bottom up. In some conditions, these contractions become weak, uncoordinated, or too infrequent. Food sits in the stomach longer than it should, fermenting and causing discomfort.
Prokinetics work by amplifying these contractions and improving coordination between different segments of the gut. Rather than just making one section squeeze harder, they help the stomach, small intestine, and sometimes the colon work together in sequence so contents actually move forward. The specific way each drug achieves this varies by class, but the end result is the same: faster, more efficient transit of food through the digestive system.
Conditions Prokinetics Treat
Gastroparesis is the most common reason prokinetics are prescribed. In gastroparesis, the stomach muscles are too weak to empty properly, causing nausea, vomiting, bloating, and early fullness. Metoclopramide is currently the only FDA-approved medication for this condition, including gastroparesis caused by diabetes.
Functional dyspepsia, or chronic indigestion without a clear structural cause, is another key use. People with this condition feel pain or discomfort in the upper abdomen after meals, and prokinetics can help by speeding up stomach emptying. Chronic nausea and vomiting that hasn’t responded to other treatments may also be managed with prokinetics.
Chronic acid reflux (GERD) sometimes involves slow stomach emptying as a contributing factor. Prokinetics alone don’t resolve GERD, but they’re occasionally prescribed alongside acid-reducing medications when delayed emptying is part of the problem. Chronic constipation is treated with a newer generation of prokinetics that target the colon specifically.
Types of Prokinetic Drugs
Prokinetics fall into several classes based on which receptors they target in the nervous system of the gut.
Dopamine blockers are the oldest and most widely used class. Metoclopramide and domperidone both work by blocking dopamine receptors in the gut wall, which removes dopamine’s natural braking effect on stomach contractions. Metoclopramide also acts on the brain’s nausea center, giving it a dual role as both a prokinetic and an anti-nausea drug. Domperidone is widely used outside the United States but is not FDA-approved.
Serotonin activators stimulate a specific serotonin receptor (5-HT4) found throughout the digestive tract. When activated, this receptor triggers stronger, more coordinated contractions. Prucalopride is the most well-known current example, used primarily for chronic constipation. In large clinical trials, about 47% of patients taking prucalopride had a meaningful increase in bowel movements per week, compared to 26% on placebo. An older drug in this class, cisapride, was pulled from most markets due to serious cardiac side effects.
Motilin activators mimic a gut hormone called motilin that naturally triggers the powerful “housekeeping” contractions your stomach makes between meals. The antibiotic erythromycin happens to activate motilin receptors, and at low doses it can significantly speed up gastric emptying. It’s sometimes prescribed off-label for gastroparesis at doses well below what you’d take for an infection.
Side Effects and Safety Concerns
The biggest safety issue with prokinetics involves metoclopramide and a movement disorder called tardive dyskinesia. This condition causes involuntary, repetitive movements of the face, tongue, and sometimes limbs, and it’s often irreversible. The risk increases the longer you take the drug and the higher your cumulative dose. The FDA requires a black box warning on metoclopramide and recommends that treatment not exceed 12 weeks. Despite this, studies of prescribing patterns show that roughly 20% of patients end up taking it longer than the recommended limit. The elderly, women, and people with diabetes face higher risk.
Cardiac rhythm disturbances are a concern across several prokinetic classes. Cisapride was withdrawn specifically because it could dangerously alter the heart’s electrical timing, leading to a potentially fatal arrhythmia. Domperidone carries a similar, though somewhat lower, cardiac risk. Even erythromycin, when used as a prokinetic, can rarely cause heart rhythm problems, particularly in people who already have risk factors for irregular heartbeat. Newer agents like prucalopride were specifically designed to avoid these cardiac effects by being more selective in which receptors they activate.
When and How They’re Taken
Most prokinetics are taken orally, typically before meals. The logic is straightforward: you want the drug working before food arrives in the stomach, so it can help process the meal efficiently. Metoclopramide, for instance, is usually taken 30 minutes before eating. Prucalopride for constipation is taken once daily, generally before breakfast. In hospital settings, erythromycin may be given intravenously for more immediate effect on stomach emptying.
Because of the safety limitations on metoclopramide, many people cycle through different prokinetics or use them only during symptom flare-ups rather than continuously. Your prescriber will typically start with the lowest effective dose and reassess regularly.
Herbal Alternatives With Clinical Evidence
A nine-herb combination sold as Iberogast (STW 5) has the strongest clinical evidence among natural prokinetic options. It contains extracts from plants including bitter candytuft, chamomile, peppermint, licorice root, and caraway, and has been used in Europe for over five decades. In head-to-head trials, it performed at least as well as cisapride for functional dyspepsia, with symptom scores dropping further in the herbal group than in the drug group. In another comparison, 72% of patients were symptom-free after Iberogast treatment versus 63% with metoclopramide. Side effects were also lower: 21% of Iberogast users reported adverse events compared to 33% on cisapride.
Iberogast works through multiple mechanisms, with different plant components relaxing the upper stomach while stimulating contractions in the lower stomach. It’s approved in several countries for both functional dyspepsia and irritable bowel syndrome. For people with mild motility symptoms or those looking to avoid the side effect profiles of prescription prokinetics, it represents a reasonable option with genuine clinical data behind it.
Why Options Remain Limited
Developing prokinetics has proven uniquely difficult because the gut’s nervous system is complex, and drugs that effectively speed up motility tend to also affect the heart or brain in unwanted ways. Cisapride worked well but caused fatal arrhythmias. Metoclopramide works well but causes irreversible movement disorders. This pattern has made regulators cautious and left patients with fewer choices than the prevalence of motility disorders would warrant.
Newer drug targets are being explored. Ghrelin receptor agonists, which mimic a hunger hormone that also stimulates stomach contractions, have shown promise in early trials. One compound, relamorelin, significantly reduced gastroparesis symptoms and accelerated stomach emptying in a large trial of people with diabetic gastroparesis. These drugs take a fundamentally different approach from older prokinetics, potentially sidestepping the cardiac and neurological risks that have plagued the field. For now, though, the practical toolkit remains small, making the choice of prokinetic a careful balance between benefit and risk for each individual patient.